06.27.2025
Science
Software-Enhanced Drugs
Breast Cancer
Where science meetssoftware.
Software as treatment.
Delivered to your phone.
Prescribed by your physician.
Click Therapeutics is redefining modern medicine with patient-centric digital treatments. Operating at the intersection of biology and technology, Click combines neuroscience with the power of software, creating a new way to treat disease.
Digital treatments, tangible outcomes.
We develop, validate, and commercialize software as prescription medical treatments for people with unmet medical needs.
Click SE
Medicine just got a digital upgrade: Software-Enhanced Drugs™
Click SE™ solutions combine software with pharmacotherapy to create software-enhanced drug™ treatments, designed to deliver added clinical benefit to patients compared to drug alone.
One powerful platform. Many ways to treat disease.
Our multimodal, platform-based approach targets disease and drives outcomes from multiple different angles, combining scientifically proven therapies with proprietary neuromodulatory mechanisms of action to deliver clinically-meaningful interventions.
Latest at Click
Recent publications
Collaborators
By embracing collaborations that build on our unique areas of expertise, we’re powering a new era of medicine.
Collaborating on:
CT-152
Collaborating on:
CT-155
Collaborating on:
CT-156
Collaborating on:
Wearables
Contact
Join us in our journey to raise the bar of modern medicine with software as treatments.
Join usStay up to date with news and updates
Click Therapeutics Today
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
INGELHEIM, Germany and RIDGEFIELD, Connecticut and NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50M Series D strategic investment and provided dedicated commercial funding to help bring CT-155 to patients, if cleared by the FDA. CT-155 was co-developed by Boehringer and Click.
In numbers
Upcoming event
Jul24Patients, Pipeline, and Promise: Software-Enhanced Drugs
Live webinar Thursday 7/24 at 1 PM ET
Speaker:
David Benshoof Klein
Founder & CEO
Fierce Pharma Virtual Webinar
Products Pipeline
Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
INGELHEIM, Germany and RIDGEFIELD, Connecticut and NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50M Series D strategic investment and provided dedicated commercial funding to help bring CT-155 to patients, if cleared by the FDA. CT-155 was co-developed by Boehringer and Click.